Together we will beat cancer

Donate

Taking on DNA repair to tackle cancer

Pioneering therapeutics targeting the damage repair mechanism of DNA polymerase theta in a range of cancers have entered human trials – we tell the story from discovery to translation.

Read More

Cancer Research UK’s charity Christmas cards now available

From snowy days in the country to festive wreaths and stockings, the shop has a design to suit every taste.

Read More

Immunotherapy approved for some people with oesophageal cancer on NHS in England

The immunotherapy drug nivolumab (Opdivo) has been made available for some people in England with oesophageal cancer, in what has been described as a ‘step change’ for people with this cancer.

Read More

Recognising the essential role of clinical research nurses

We hear from Rosie Lomas – the ‘Excellence in Cancer Research Nursing Award’ winner – and the other shortlisted nurses about their work and the vital role they play in delivering clinical trials.

Read More

Black in Cancer – That Cancer Conversation

This entry is part 3 of 3 in the series That Cancer Conversation

From groundbreaking rare cancer research to ending up on Forbes 30 under 30, we chat to Sigourney Bell about her work in the lab and her global organisation, Black in Cancer.

Read More

New drug available for rare thyroid cancer on NHS in England

The National Institute for Health and Care Excellence (NICE) has recommended the use of the drug selpercatinib (Retevmo) for some people in England with a type of advanced thyroid cancer.

Read More

Making the most of your ‘eureka’ moment: getting from the science to the clinic

How can we make the vital journey from research to clinical impact more efficient? It all comes down to empowering researchers to develop an entrepreneurial mindset

Read More

Cancer target missed for 55,000 patients over 6 years

In the last 6 years, almost 55,000 cancer patients should have been diagnosed or started their treatment sooner, according to new calculations.

Read More

Combining existing drugs improves prostate cancer survival

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer, according to findings presented at the ESMO conference.

Read More

How cancer hijacks cell death: a new view of metastasis

Professor Jody Rosenblatt tells us why dysregulated cell death could have an impact not only on metastasis, but also therapy resistance.

Read More